GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in…

• NI
  National Institutes of Health

  Awards: U24 DK132733, DK040561, P30 DK040561, UE5 DK137285
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Awards: UE5 DK137285, DK040561, U24 DK132733, P30 DK040561